Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

"As with any rapid technological development, the biotechnology revolution is putting great strains on the ability of law to adapt to new challenges and threats. Although there is general agreement on the need to regulate biotechnology in many different fields of human activity (agriculture, life sciences, forensic science) domestic law remains deeply divided over the best approach to take. This book is the first attempt at covering the most pressing legal issues raised by the impact of biotechnologies on different categories of international norms. Through the contribution of a selected group of international scholars and experts from international organizations, the book addresses. 1) the international status of genetic resources, both in areas of national jurisdiction and in common spaces such as the international sea bed area and Antarctica; 2) the relevance of environmental principles in the governance of modern biotechnologies; 3) the impact of biotechnologies on trade rules, including intellectual property law; 4) the human rights implications, especially in the field of human genetics; and 5) the intersection between general international law and regional systems, especially those developed in Europe and Latin America. The overall objective of the book is to provide an up-to-date picture of international law as it stands today and to stimulate critical reflection and further research on the solutions that will be required in years to come."--Bloomsbury Publishing.

Biotechnology industry.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

From a managerial perspective, the biopharmaceutical industry represents a competitive, fast-changing, intellectually-powered, innovation-driven sector. Many management scholars have studied this discontinuous era to make sense of strategic behavior and the cognition of firms and top managers. A past look at the biopharmaceutical industry provides answers to questions that most managers have. For example, what options do you have and what actions do you take when new firms enter your industry? In the 1970s, new biotechnology firms, funded by venture capitalists, appeared in the pharmaceutical industry with new knowledge. Successful pharmaceutical firms decided to collaborate with the new entrants and forge relationships to develop and create new, biotechnology engineered drugs. Thus, the addition of new biotechnology firms ushered in a new business model based on strategic alliances. Strategic alliances have now become an industrial norm called open innovation. The author looks at the historical path of the biopharmaceutical industry, particularly in the United States. While the pharmaceutical industry’s main contributions to society are substantial, there are pressing challenges the industry must face, such as an increase in infectious disease outbreaks or the global aging population, which require new types of care, additionally, mental health care and prescription painkiller addiction are persistent issues with economic repercussions to both federal and local governments. This book presents a holistic view of the biopharmaceutical industry, putting it in a historical context. It will best serve those who are eager to learn about this dynamic, fast-evolving industry andwho would like to tackle current biopharmaceutical industry issues in the United States and be prepared for future industry challenges.

Pharmaceutical biotechnology industry --- Pharmaceutical biotechnology --- History.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

microbiology --- virology --- bacteriology --- Pharmaceutical industry --- Pharmaceutical biotechnology industry --- Biotechnology industries --- Pharmaceutical industry. --- Pharmaceutical biotechnology industry. --- Drug industry --- Drug trade --- Medicine industry --- Medicines industry --- Prescription medicine industry --- Chemical industry

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

"At the start of 2020, Moderna was a waning biotech unicorn, still years away from delivering its first product despite a decade of development of a potentially breakthrough innovation: using RNA to combat disease. Investors were getting antsy or, worse, skeptical. Then the coronavirus pandemic hit, and Moderna became a central player in a global drama-a David to pharma's Goliaths-turning its technology toward breaking the global grip of the terrible disease. By year's end, as the outbreak was at its worst, Moderna delivered one of the world's first Covid-19 vaccines, with a stunningly high rate of protection. The achievement not only offered the world a way out of a crippling pandemic but also validated Moderna's gene-based technology, transforming the company into a global industry power, swelling its market value on its prospects for new drugs and vaccines for years to come. Biotech, and the venture capital community that fuels it, will never be the same. Wall Street Journal reporter Peter Loftus, part of a Pulitzer Prize-finalist reporting team and 25-year veteran reporter in the pharmaceutical and biotech industries, brings the inside story of how Moderna went all in on a single revolutionary idea; of quiet research with unknown consequence; of the evolution of a cutting-edge American innovation, industry, and economy-decades in the making-that led to one of the great gambles in business history"--

Vaccines industry --- Pharmaceutical biotechnology industry --- Messenger RNA. --- History. --- Economic aspects --- History. --- Moderna (Firm) --- History.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Transform your research into commercial biomedical products with this revised and updated second edition. Covering drugs, devices and diagnostics, this book provides a step-by-step introduction to the process of commercialization, and will allow you to create a realistic business plan to develop your ideas into approved biomedical technologies. This new edition includes: Over 25% new material, including practical tips on startup creation from experienced entrepreneurs. Tools for starting, growing and managing a new venture, including business planning and commercial strategy, pitching investors, and managing operations. Global real-world case studies, including emerging technologies such as regulated medical software and Artificial Intelligence (AI), offer insights into key challenges and help illustrate complex points. Tips and operational tools from established industry insiders, suitable for graduate students and new biomedical entrepreneurs.

Biomedical engineering --- Pharmaceutical biotechnology industry --- Pharmaceutical biotechnology --- Medical instruments and apparatus --- Marketing. --- Patents. --- Marketing